Page last updated: 2024-11-02

oxybutynin and Supranuclear Palsy, Progressive

oxybutynin has been researched along with Supranuclear Palsy, Progressive in 1 studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Supranuclear Palsy, Progressive: A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schirinzi, T1
Pisani, V1
Imbriani, P1
Di Lazzaro, G1
Scalise, S1
Pisani, A1

Other Studies

1 other study available for oxybutynin and Supranuclear Palsy, Progressive

ArticleYear
Long-term treatment with rotigotine in drug-naïve PSP patients.
    Acta neurologica Belgica, 2019, Volume: 119, Issue:1

    Topics: Aged; Dopamine Agonists; Female; Humans; Male; Middle Aged; Supranuclear Palsy, Progressive; Tetrahy

2019